FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Fusco MJ, Casak SJ, Mushti SL, Cheng J, et al. Clin Cancer Res 2024 May 29. doi: 10.1158/1078-0432.CCR-24-0281.

Read + Share

Amedeo Smart

Independent Medical Education

Fusco MJ, Casak SJ, Mushti SL, Cheng J, et al. FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clin Cancer Res 2024 May 29. doi: 10.1158/1078-0432.CCR-24-0281.
PMID: 38809262